All In Biotech

Drug Trial Radar · NCT06164730

A Study of VERVE-102 in Patients With Familial Hypercholesterolemia or Premature Coronary Artery Disease

Open-label, Phase 1b, Single Ascending Dose Study to Evaluate the Safety of VERVE-102 Administered to Patients With Heterozygous Familial Hypercholesterolemia or Premature Coronary Artery Disease Who Require Additional Lowering of Low-density Lipoprotein Cholesterol

Last checked: Nov 19, 2026Latest source record: Sep 2, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Recruiting

Status

Recruiting

Enrollment

85

Planned (sponsor's estimate)

Start

Apr 30, 2024

Primary completion

Oct 2026

Study completion Oct 2027

Sponsor

Lead sponsor
Eli Lilly and CompanyEli Lilly (LLY)
Sponsor type
Industry
First posted
Dec 11, 2023

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 1
Allocation
Non randomized
Model
Sequential
Masking
None
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years, up to 70 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

VT-10201 is an Open-label, Phase 1b, Single-ascending Dose Study That Will Evaluate the Safety of VERVE-102 Administered to Patients With Heterozygous Familial Hypercholesterolemia (HeFH) or Premature Coronary Artery Disease (CAD) Who Require Additional Lowering of LDL-C. VERVE-102 Uses Base-editing Technology Designed to Disrupt the Expression of the PCSK9 Gene in the Liver and Lower Circulating PCSK9 and LDL-C. This Study is Designed to Determine the Safety and Pharmacodynamic Profile of VERVE-102 in This Patient Population.

Conditions

  • Heterozygous Familial Hypercholesterolemia
  • Premature Coronary Heart Disease

Interventions

  • VERVE-102Drug

    Intravenous (IV) infusion

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Incidence of treatment-emergent adverse events (TEAEs) and serious adverse events (SAEs)Time frame: up to Day 365

Locations

27 sites in 6 countries. Site status is shown where the registry gives one.

  • Clinical Study Center

    Dothan, Alabama · Recruiting

  • Clinical Study Center

    Pomona, California · Recruiting

  • Clinical Study Center

    Boca Raton, Florida · Recruiting

  • Clinical Study Center

    Jacksonville, Florida · Recruiting

  • Clinical Study Center

    Winter Park, Florida · Recruiting

  • Clinical Study Center

    Indianapolis, Indiana · Recruiting

  • Clinical Study Center

    High Point, North Carolina · Recruiting

  • Clinical Study Center

    Philadelphia, Pennsylvania · Recruiting

  • Clinical Study Center

    DeSoto, Texas · Recruiting

  • Clinical Study Center

    Renton, Washington · Recruiting

  • Clinical Study Center

    Adelaide, Australia · Recruiting

  • Clinical Study Center

    Melbourne, Australia · Recruiting

  • Clinical Study Center

    Sydney, Australia · Recruiting

  • Clinical Study Center

    Chicoutimi, Canada · Recruiting

  • Clinical Study Center

    Hamilton, Canada · Recruiting

  • Clinical Study Center

    Montreal, Canada · Recruiting

  • Clinical Study Center

    Québec, Canada · Recruiting

  • Clinical Study Center

    Toronto, Canada · Recruiting

  • Clinical Study Center

    Vancouver, Canada · Recruiting

  • Clinical Study Center

    Rehovot, Israel · Recruiting

  • Clinical Study Center

    Christchurch, New Zealand · Recruiting

  • Clinical Study Center

    Birmingham, United Kingdom · Recruiting

  • Clinical Study Center

    Cambridge, United Kingdom · Recruiting

  • Clinical Study Center

    Edinburgh, United Kingdom · Recruiting

  • Clinical Study Center

    London, United Kingdom · Recruiting

  • Clinical Study Center

    Manchester, United Kingdom · Recruiting

  • Clinical Study Center

    Nottingham, United Kingdom · Recruiting

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.